The aim of this study is to find which of the factors available in routine clinical practice can accurately predict, in HER2 BC, pCR after PST so that we can translate these results to surgical planning in de-escalation mode, both in the breast and in the axilla, without missing oncologic safety. The gene discussed is ERBB2; the disease is breast cancer.